nafamostat has been researched along with Bone Neoplasms in 1 studies
nafamostat: inhibitor of trypsin, plasmin, pancreatic kallikrein, plasma kallikrein & thrombin; strongly inhibits esterolytic activities of C1r & C1 esterase complement-mediated hemolysis; antineoplastic
Bone Neoplasms: Tumors or cancer located in bone tissue or specific BONES.
Excerpt | Relevance | Reference |
---|---|---|
"Bone metastases from gastric cancer (GC) are considered a relatively uncommon finding; however, they are related to poorer prognosis." | 2.52 | Targeting mast cells in gastric cancer with special reference to bone metastases. ( Ammendola, M; De Sarro, G; Gadaleta, CD; Leporini, C; Marech, I; Oakley, C; Ranieri, G; Russo, E; Sacco, R; Sammarco, G, 2015) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Leporini, C | 1 |
Ammendola, M | 1 |
Marech, I | 1 |
Sammarco, G | 1 |
Sacco, R | 1 |
Gadaleta, CD | 1 |
Oakley, C | 1 |
Russo, E | 1 |
De Sarro, G | 1 |
Ranieri, G | 1 |
1 review available for nafamostat and Bone Neoplasms
Article | Year |
---|---|
Targeting mast cells in gastric cancer with special reference to bone metastases.
Topics: Animals; Antigens, CD34; Benzamides; Benzamidines; Bone and Bones; Bone Neoplasms; Bone Resorption; | 2015 |